TMO
Thermo Fisher Scientific Inc.
- Selling, general and administrative, 2025
- $8.7B
- YoY, 2025
- +1.6%
- 5-year CAGR
- +4.7%
- 10-year CAGR
- +6.6%
Selling, general and administrative
Selling, general and administrative by fiscal year
| Period | SG&A | YoY |
|---|---|---|
| 2025 | $8.7B | +1.6% |
| 2024 | $8.6B | +1.8% |
| 2023 | $8.4B | −6.1% |
| 2022 | $9.0B | +12.3% |
| 2021 | $8.0B | +15.5% |
| 2020 | $6.9B | +12.8% |
| 2019 | $6.1B | +1.4% |
| 2018 | $6.1B | +10.0% |
| 2017 | $5.5B | +10.7% |
| 2016 | $5.0B | +7.8% |
| 2015 | $4.6B | −5.8% |
| 2014 | $4.9B | +42.1% |
| 2013 | $3.4B | +2.7% |
| 2012 | $3.4B | +8.0% |
| 2011 | $3.1B | +13.8% |
| 2010 | $2.7B | +5.2% |
| 2009 | $2.6B | −3.7% |
| 2008 | $2.7B | +5.6% |
| 2007 | $2.5B | — |